3F8 monoclonal antibody

anti-GD2 monoclonal antibody · Memorial Sloan Kettering Cancer Center

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for 3F8 monoclonal antibody, covering 2020-02-28 to 2022-05-16. Get the full timeline:

Most recent: Clinical Trial Update: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma [Phase 2]